trial

Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

NCTId NCT02949232
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 42 (actual)
Sponsored by UMC Utrecht
Primary completion 2019-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
42 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-07
Primary completion
2019-05
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Prednisolone

Sponsors

UMC UtrechtLead Sponsor

Investigators

1
Iris E.C. Sommer, Prof. Dr.Principal Investigator

Sites

4 total
Antwerp, BelgiumRisskov, DenmarkSliedrecht, NetherlandsUtrecht, Netherlands

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE4
Primary Completion Date
2019-05
Status
TERMINATED
relationships
The graph out of here
drug
Prednisolone
drug
lead_sponsor
UMC Utrecht
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorder NOS
indication
investigator
Iris E.C. Sommer, Prof. Dr.
person